Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts.
Lipid-based dose forms, which encompass a wide variety of compositional and functional characteristics, can be advantageously utilized for the formulation of lipophilic drugs. There has been a traditional reluctance to develop lipid-based dose forms due to potential problems of chemical and physical instability, and a paucity of knowledge regarding formulation design algorithms and technology transfer issues. However, there is a current resurgence of interest in lipid-based dose forms due to potential commercial and pharmaceutical benefits, and the industry trend towards the discovery/development of increasingly hydrophobic (and potent) new chemical entities. This mini-review describes some emerging formulation and biopharmaceutic strategies that hold promise for better understanding how to design and evaluate lipid-based dose forms.
Charman
W N
WN
Department of Pharmaceutics, Victorian College of Pharmacy, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia. bill.charman@vcp.monash.edu.au
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D002626:Chemistry, Pharmaceutical; D016503:Drug Delivery Systems; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000166:cytology; D008055:Lipids / Q000008:administration & dosage*; D008074:Lipoproteins / Q000097:blood; D008208:Lymphatic System / Q000378:metabolism; D012995:Solubility
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D008055:Lipids; D008074:Lipoproteins